Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers [PDF]
, 2016 Osteopontin (OPN) is a secreted glycoprotein, that belongs to the non-structural extracellular matrix (ECM), and its over expression in human prostate cancer has been associated with disease progression, androgen independence and metastatic ability ...
Arioli, I. +9 more
core +2 more sources
Cancer Medicine, 2020 Background Recently approved second‐generation androgen receptor inhibitors (SGARIs) for non‐metastatic castration‐resistant prostate cancer (nmCRPC) have similar efficacy but differ in safety profiles.
Sandy Srinivas +9 more
doaj +1 more source
Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score [PDF]
, 2001 CONTEXT: Multiple genetic and epigenetic factors have been implicated in the oncogenesis and progression of prostate cancer. The major difficulty is in that the clinical management stems from the reality that reliable and accurate prognostic biomarkers ...
Hering, Flavio Luis Ortiz +5 more
core +1 more source
Galectins as New Prognostic Markers and Potential Therapeutic Targets for Advanced Prostate Cancers [PDF]
, 2013 A better understanding of multimolecular interactions involved in tumor dissemination is required to identify new effective therapies for advanced prostate cancer (PCa).
Compagno, Daniel Georges +3 more
core +3 more sources
Research and Reports in Urology, 2022 Nicolas Fernandez,1 Julian Chavarriaga,2 Paola Ayala,3 Adriana Pedraza,4 John Bolivar,5 Juan Guillermo Prada,6 Juan Guillermo Cataño,6 Herney Garcia,7 Juliana Villanueva,6 Daniela Varela,6 Ignacio Zarante3 1Division of Urology Seattle Children’s Hospital,
Fernandez N +10 more
doaj
The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castrationresistant prostate cancer: Post hoc analysis of Korean patients [PDF]
Investigative and Clinical Urology, 2016 Purpose: This post hoc analysis evaluated treatment effects, safety, and pharmacokinetics of enzalutamide in Korean patients in the phase 3, double-blind, placebo-controlled PREVAIL trial.
Choung-Soo Kim +7 more
doaj +1 more source
Does true Gleason pattern 3 merit its cancer descriptor? [PDF]
, 2016 Nearly five decades following its conception, the Gleason grading system remains a cornerstone in the prognostication and management of patients with prostate cancer.
A El-Shater Bosaily +117 more
core +1 more source
Up-regulated expression of LAMP2 and autophagy activity during neuroendocrine differentiation of prostate cancer LNCaP cells [PDF]
, 2016 Neuroendocrine (NE) prostate cancer (PCa) is a highly aggressive subtype of prostate cancer associated with resistance to androgen ablation therapy. In this study, we used LNCaP prostate cancer cells cultured in a serum-free medium for 6 days as a NE ...
A Ibrahim-Hashim +69 more
core +9 more sources
Prognostic and predictive biomarkers in prostate cancer [PDF]
, 2015 Prostate cancer (PCa) is one of the leading causes of cancer death among males, especially in more developed countries. Diagnosis is often achieved at an early stage of the disease with prostate biopsy, following a screening test showing elevated serum ...
Adamopoulos, Panagiotis G +2 more
core +1 more source
Radium-223 dichloride: a new paradigm in the treatment of prostate cancer [PDF]
, 2015 Review[Abstract] Radionuclides have been widely used for cancer treatment. Recently, new research about radium-223 dichloride has been conducted in prostate cancer, which reveals that it is the first radiopharmaceutical to demonstrate an improvement in ...
Afonso Afonso, Francisco Javier +7 more
core +2 more sources